江苏恩华药业股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 1、公司参与人员：公司总经理孙家权、独立董事陈国祥、董事会 | | | 秘书段保州、财务负责人李岗生。 | | | 2、参与的投资者详见附件。 | | 时间 | 2023 年 3 月 28 日下午 15:00-17：00 | | 地点 | 全景网"投资者关系互动平台" （https://ir.p5w.net） | | 形式 | 采用网络远程的方式 | | 交流内容及具体问答记 | 详见附件。 | | 录 | | | 关于本次活动是否涉及 | 本次活动未涉及应披露重大信息。 | | 应披露重大信息的说明 | | | 活动过程中所使用的演 | 无。 | | 示文稿、提供的文档等 | | | 附件（如有，可作为附 | | | 件） | | 附件： 江苏恩华药业股份有限公司 2022 年度业绩说 ...

Financial Performance - The company's operating revenue for 2022 was ¥4,298,513,062.14, representing a year-on-year increase of 9.22% from ¥3,935,664,219.52 in 2021[13]. - The net profit attributable to shareholders for 2022 was ¥900,926,029.55, which is a 12.93% increase compared to ¥797,777,327.57 in 2021[13]. - The basic earnings per share for 2022 was ¥0.89, up 12.66% from ¥0.79 in 2021[13]. - The total assets at the end of 2022 amounted to ¥6,481,745,574.76, reflecting a 13.77% increase from ¥5,697,186,706.05 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥5,622,248,624.37, which is a 14.26% increase from ¥4,920,688,031.43 at the end of 2021[13]. - In Q4 2022, the operating revenue reached ¥1,178,387,350.86, with a net profit attributable to shareholders of ¥159,051,214.46[16]. - The company reported a cash flow from operating activities of ¥861,023,149.69 for the year 2022, which is a 22.81% increase from ¥701,117,596.67 in 2021[13]. - The company recognized government subsidies amounting to ¥46,912,734.05 in 2022, compared to ¥32,743,590.42 in 2021[17]. - The weighted average return on equity for 2022 was 17.20%, slightly down from 17.69% in 2021[13]. - The company reported a total of ¥28,166,708.35 in non-recurring gains and losses for 2022[17]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The proposed cash dividend for 2022 is ¥2.00 per 10 shares, totaling ¥201,517,618.40, with no stock dividends or capital reserve transfers[133]. - The cumulative cash dividend amount from 2019 to 2021 was approximately ¥604.19 million, accounting for 82.77% of the average annual net profit during the same period[153]. - After the dividend distribution, the retained undistributed profit will be ¥3,776,835,195.20, to be carried forward for future distribution[133]. Market and Industry Trends - The pharmaceutical industry in China is experiencing significant growth, with healthcare expenditure as a percentage of GDP reaching 4.83% in 2022, indicating a rising demand for medical services[21]. - Chronic disease prevalence in China has reached 23%, with chronic diseases accounting for 86% of total deaths, leading to increased long-term medication and healthcare costs[21]. - The central nervous system (CNS) drug market in China is still in its early stages, with only 3% of the global CNS drug consumption, compared to 49% in the US and 26% in Europe[23]. - The aging population and rising health awareness among the public are expected to drive further growth in the pharmaceutical sector, presenting significant opportunities for companies like Jiangsu Enhua[22]. - The ongoing healthcare reforms and policies, such as centralized procurement, are pushing pharmaceutical companies to innovate and improve their R&D capabilities[21]. Research and Development - The company has a robust product pipeline with 22 innovative drug projects and 38 generic drug projects currently under development, alongside 15 projects undergoing consistency evaluation[23]. - The company increased R&D investment to CNY 495,383,504.42, a growth of 23.10% compared to the previous year, with over 70 ongoing research projects[30]. - There are currently 22 innovative drug projects under development, including 1 in Phase II clinical trials and 4 in Phase I clinical trials, with 5 projects expected to submit clinical applications in 2023[30]. - The company has launched 38 generic drug projects, with 2 generic drug production approvals obtained during the reporting period[30]. - The company has applied for 127 invention patents and received 44 authorized invention patents during the reporting period[30]. Corporate Governance - The company reported a commitment to improving corporate governance, aligning with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, enhancing internal control systems[97]. - The board of directors consists of four independent directors, exceeding one-third of the total board members, ensuring compliance with governance standards[98]. - The company has established a mechanism to prevent major shareholders from occupying company funds, safeguarding the interests of minority shareholders[97]. - The company emphasizes transparent communication with investors, implementing various channels for interaction, including online platforms and direct communication[99]. - The company has a comprehensive human resources management system that includes detailed regulations on recruitment, training, compensation, and performance evaluation[154]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, ensuring wastewater and air emissions meet national standards[143]. - The company invested approximately CNY 15.22 million in environmental governance and protection, including the purchase of environmental protection equipment and facility upgrades[151]. - The company implemented a wastewater treatment system with a capacity of 800 tons per day at the Jinshanqiao plant, ensuring that treated wastewater meets discharge standards[146]. - The company achieved over 95% efficiency in VOC treatment after upgrading its exhaust gas treatment systems, with an investment of CNY 3 million in 2022[147]. - The company has not faced any administrative penalties related to environmental issues in 2022[152]. Social Responsibility - The company actively participates in charitable activities, contributing medicines and funds to local poverty alleviation efforts, enhancing its social responsibility image[99]. - The company has established the "Enhua Caring Fund," which has donated a total of 807,800 yuan to assist socially disadvantaged families over the past seven years[159]. - The company collaborates with Nanjing Medical University to provide 60,000 yuan in scholarships annually to outstanding students in the field of psychiatry[159]. - The company has committed 480,000 yuan to support rural revitalization efforts, directly benefiting local communities[160]. - The company has been fulfilling its social responsibilities by supporting education, culture, science, and health initiatives in local areas[159]. Future Outlook - The company aims for approximately 15% growth in business revenue, total profit, and net profit in 2023 compared to the audited data of 2022[86]. - The company plans to advance 6 innovative drug clinical trials in 2023 and aims to establish 3-5 new innovative drug projects, with a goal of submitting 5 innovative drug applications for clinical trials[86]. - The company is focusing on high-barrier generic drugs and has 4 projects undergoing consistency evaluation, with 3 expected to be approved in 2023[87]. - The company is enhancing its marketing strategies to strengthen new product market access and aims to maintain its leading position in the central nervous system drug sector[88]. - The company is committed to optimizing production management and cost control, with a focus on improving product quality and reducing complaints[87].

江苏恩华药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002262 证券简称：恩华药业 公告编号：2023-012 江苏恩华药业股份有限公司（以下简称"公司"）定于2023年3月28日（星期二）15:00- 17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 公司出席本次说明会的人员有：公司总经理孙家权、董事会秘书段保州、财务负责人李 岗生、独立董事陈国祥。 问题征集专题页面二维码 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前向投资者公 开征集问题，广泛听取投资者的意见和建议。投资者可于2023年3月27日（星期一）17：00前 访问https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。公司将在2022年度业 绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会 ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥3.36 billion, a decrease of 18.99% compared to ¥4.15 billion in 2019[20]. - Net profit attributable to shareholders for 2020 was approximately ¥728.82 million, an increase of 9.88% from ¥663.31 million in 2019[20]. - The net cash flow from operating activities surged by 307.99% to approximately ¥1.25 billion, compared to ¥305.97 million in 2019[20]. - Basic earnings per share for 2020 were ¥0.72, reflecting a 9.09% increase from ¥0.66 in 2019[20]. - Total assets at the end of 2020 reached approximately ¥4.75 billion, a growth of 13.02% from ¥4.20 billion at the end of 2019[20]. - Net assets attributable to shareholders increased by 13.87% to approximately ¥4.12 billion, up from ¥3.62 billion in 2019[20]. - The company reported a weighted average return on equity of 18.42%, down from 20.22% in the previous year[20]. - The fourth quarter of 2020 saw the highest quarterly revenue of approximately ¥986.79 million[24]. - The net profit attributable to shareholders in the fourth quarter was approximately ¥157.40 million[24]. - The company reported a total of ¥18,495,326.74 in non-recurring gains and losses, a decrease from ¥60,640,785.26 in 2019[26]. Research and Development - The company is committed to significant investment in drug research and development, with a focus on innovation and consistency evaluation of generic drugs, which may involve high costs and long timelines[6]. - The company has over 70 ongoing research projects, with 18 projects undergoing consistency evaluation, including two new specifications for existing products[30]. - There are 39 key generic drug projects in development, with 20 at various stages of research and 19 projects under confidentiality[30]. - The company applied for 65 invention patents during the reporting period, with 30 patents granted, including one awarded the first Xu Zhou Patent Gold Award[30]. - The company has established a comprehensive R&D platform for CNS drugs, with a focus on high-potential and high-barrier products[44]. - The company invested CNY 245,863,036.38 in R&D during the reporting period, representing a 30.10% increase compared to the previous year, enhancing its core competitiveness through the successful development of new products with independent intellectual property rights[46]. - The company has 20 innovative drug projects in progress, with 16 projects at different stages of development[47]. - The company expects to submit IND applications for several new drugs in 2021 and 2022, including NH600001 and NH100, which are classified as innovative drugs[49]. Market Strategy and Expansion - The company is focusing on professionalizing its sales force and adjusting sales strategies to adapt to the centralized procurement model, aiming to increase market share for non-procurement products[34]. - The company aims to maintain stable revenue from procurement products in procurement areas while expanding sales in non-procurement regions[34]. - The company is actively pursuing innovation, with several new drug candidates expected to submit IND applications in 2021 and 2022, reflecting its commitment to R&D[32]. - The company is positioned in a weak cyclical industry, with a strong emphasis on controlling medical insurance costs through centralized procurement, which is reshaping the pharmaceutical landscape[36]. - The company plans to accelerate the internationalization of its raw materials and formulations, while focusing on product structure adjustments[40]. - The company is pursuing international expansion by promoting FDA re-certification and seeking collaborations with foreign pharmaceutical companies[143]. - The company plans to open 10-30 chain psychological clinics nationwide through its subsidiary, enhancing its online medical platform[144]. Risk Management - The company faces risks from industry policy changes, including stricter drug approval and quality regulations, which could impact future operations[4]. - Environmental risks are present due to potential pollution from production processes, necessitating compliance with national environmental policies[6]. - The company acknowledges a risk of talent shortages as it expands, which may affect strategic execution and management[6]. - The company emphasizes the importance of quality control in drug production, as any operational missteps could adversely affect product quality and business performance[4]. - The company is committed to addressing potential risks, including environmental and talent shortages, to ensure the achievement of its 2021 operational goals[155]. - New GMP standards and regulations impose stricter quality control requirements throughout the drug development process, increasing operational risks[155]. Corporate Governance and Compliance - The company has established a comprehensive governance structure to ensure accountability and transparency in its operations[3]. - The company did not experience any changes in its main business or controlling shareholders since its listing[19]. - The company has complied with all regulations regarding the management of raised funds[124]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[172]. - There were no significant accounting errors that required retrospective restatement during the reporting period[182]. Dividend Policy - The company reported a profit distribution plan, proposing a cash dividend of 1 RMB per 10 shares, based on a total of 1,007,588,092 shares[7]. - The total cash dividend, including other methods, amounts to 300,758,707.08 yuan, representing 100% of the distributable profit[165]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase with significant capital expenditure plans[165]. - Over the past three years, the company's cash dividend payout ratios have been 13.82% in 2020, 15.36% in 2019, and 11.66% in 2018, reflecting a consistent return to shareholders[164].

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching 1.5 billion RMB, representing a year-on-year growth of 15%[1]. - The net profit attributable to shareholders for the same period was 300 million RMB, an increase of 20% compared to the previous year[1]. - The company's operating revenue for the reporting period reached ¥1,865,023,379.80, representing a 25.81% increase compared to ¥1,482,401,437.22 in the same period last year[22]. - Net profit attributable to shareholders was ¥410,905,547.89, up 16.46% from ¥352,815,134.46 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥416,285,999.28, reflecting a 17.50% increase from ¥354,271,558.63 in the previous year[22]. - The company achieved operating revenue of ¥1,865,023,379.80, representing a year-on-year growth of 25.81%[29]. - The net profit attributable to shareholders reached ¥410,905,547.89, an increase of 16.46% compared to the same period last year[29]. - The company reported a total of ¥17,369,293.56 in investment income from financial products, which is considered a recurring gain due to its frequency and relevance to normal business operations[26]. - The company received government subsidies amounting to ¥678,000.00, which are closely related to its business operations[26]. - The company expects a net profit for the period from January to September 2021 to be between ¥628,562,000 and ¥742,846,000, representing a growth of 10.00% to 30.00% compared to the previous year[86]. - Basic earnings per share are projected to be between ¥0.62 and ¥0.73, reflecting an increase of 10.71% to 30.36% year-on-year[86]. Research and Development - The company plans to invest 200 million RMB in research and development for new drug innovations and consistency evaluations in the upcoming year[1]. - The company has over 70 ongoing research projects, including 19 projects for consistency evaluation[32]. - There are 38 key generic drug projects under research, with 15 innovative drug projects also in progress[32]. - The company applied for 17 invention patents during the reporting period, with 5 patents granted[32]. - The company invested approximately 157 million yuan in R&D during the reporting period, representing a 53.94% increase compared to the same period last year[44]. - Research and development expenses rose by 53.94% to ¥156,570,685.07, reflecting increased investment in product development during the reporting period[64]. - The company has built a comprehensive R&D platform for innovative drugs, particularly in the field of psychotropic and analgesic drugs[57]. - The company is focusing on enhancing its research and development efforts to drive innovation and market competitiveness[193]. Market Expansion and Strategy - Future outlook includes a projected revenue growth of 10-15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[1]. - The company is actively expanding its market presence despite increased competition and regulatory challenges in the pharmaceutical industry[29]. - The strategic focus remains on technological innovation and internal management enhancement to ensure sustainable development[29]. - The company aims to expand the sales scale of non-centralized procurement products and maintain stable revenue for centralized procurement products in their respective regions[40]. - The company is actively pursuing the development of innovative drugs, with several products expected to submit IND applications in 2022[39]. - The company is committed to increasing its investment in innovative drugs and high-barrier generic drugs[31]. - The company aims to accelerate the internationalization of its raw materials and formulations while focusing on high-potential and high-barrier products[46]. Environmental Compliance - Environmental compliance measures are being prioritized to mitigate risks associated with production waste and pollution[1]. - The company invested approximately 70 million RMB in upgrading VOCs collection and treatment projects, which were completed and put into operation by the end of June 2021[51]. - The company has implemented a comprehensive environmental monitoring plan, with all monitored parameters meeting regulatory requirements in the first half of 2021[107]. - The company has strengthened its sales team and adjusted sales strategies to enhance market share, particularly for non-collection products[46]. - The company has established a charity fund, donating a total of 782,800 RMB to assist socially disadvantaged families over the past five years[109]. Shareholder and Corporate Governance - No cash dividends or stock bonuses will be distributed to shareholders for this period, as the company aims to reinvest profits into growth initiatives[1]. - The company held its annual general meeting on April 2, 2021, with an investor participation rate of 2.01%[89]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[91]. - The company completed the repurchase and cancellation of 414,000 restricted shares from 17 former employees, reducing total shares from 1,020,015,711 to 1,019,601,711[92]. - The company has maintained its independent operational status and will not engage in transactions that could harm the interests of shareholders[114]. - The company has ensured that any business opportunities that could compete with its operations will be directed to the company itself[113]. - The company has established a three-year agreement among its major shareholders to maintain consistent actions regarding shareholding[115]. Risks and Challenges - The company acknowledges the risk of high-end talent shortages as it scales operations and expands its business[1]. - The company faces risks related to industry policy changes, quality control, and the need for high-end talent as it expands its operations[54]. - The company reported no violations regarding external guarantees during the reporting period[118]. - The company did not experience any penalties or rectification situations during the reporting period[122]. - The company has not engaged in any related party transactions during the reporting period[123].